Tous Actualités
Suivre
Abonner Isotechnika Inc.

Isotechnika Inc.

Isotechnika Receives Approval From the German Competent Authority for a Pivotal Phase III Psoriasis Clinical Trial

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. announced
today that the Company received approval  from the German Competent
Authority to conduct a pivotal Phase III clinical  trial for the
treatment of moderate to severe psoriasis with its lead
immunosuppressive drug, ISA247.
The Phase III European/Canadian psoriasis trial (ESSENCE trial)
will  be performed over a 24 week period at a total of thirty-six
centers in  Germany, Poland and Canada involving a total of 500
patients with moderate  to severe psoriasis. The trial will be
conducted as a randomized, orally  administered placebo and
cyclosporine controlled study with 300 patients  receiving ISA247
(0.4 mg/kg twice daily), 100 patients receiving  cyclosporine (1.5
mg/kg twice daily), and 100 patients receiving placebo.  In an effort
to maximize the benefit to patients enrolled in the placebo  group
ISA247 will be administered at a dose of 0.4 mg/kg twice daily
following the first 12 weeks.
Successful completion of the trial will be determined by the
following  endpoints;
     Primary endpoint
     -  superiority in the proportion of subjects achieving a score of
        "clear" or "almost clear" in the Static Physician's Global Assessment
        (SPGA) score at 12 weeks in the ISA247 treatment group compared to
        placebo control.
     Secondary endpoints
     -  non-inferiority of ISA247 compared to cyclosporine control in the
        proportion of subjects achieving a score of "clear" or "almost clear"
        in the Static Physician's Global Assessment (SPGA) score at 12 weeks;
     -  a 75% reduction in the Psoriasis Area and Severity Index (PASI) score
        at 12 weeks of ISA247 versus placebo; and
     -  maintenance of stable kidney function.
"Moving our late-stage clinical development plan for ISA247
forward in  psoriasis and kidney transplantation continues to be our
primary focus,"  stated Dr. Randall Yatscoff, Isotechnika's President
& CEO. "Following our  first phase III psoriasis trial approval and
subsequent completion in  Canada, this second phase III approval for
moderate to severe psoriasis now  allows us the opportunity to expand
our trials into Europe. In anticipation  of this approval, clinical
trial sites have been selected. Patient  enrollment will commence
later this year."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in  medicinal chemistry and immunology, the Company is
focused on the discovery  and development of novel immunosuppressive
therapeutics that are safer than  currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug  candidates for
treatment of autoimmune diseases and for use in the  prevention of
organ rejection in transplantation. Isotechnika looks to  become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 has completed an extension
protocol of a Canadian Phase III human clinical trial for the
treatment of  moderate to severe psoriasis and a North American Phase
IIb human clinical  trial for the prevention of kidney graft
rejection. The Company also has an  additional immunosuppressive
compound in its drug pipeline, TAFA93 which  successfully completed
Phase I clinical trials.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found  at www.isotechnika.com.
Partnerships with Isotechnika Inc.
Isotechnika Inc. has a collaboration agreement with Hoffman La
Roche  which licensed the worldwide rights to develop and
commercialize ISA247 for  all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use  of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue  disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive  license to develop and commercialize conjugates consisting
of Cellgate's  patented transporter technology for the topical
delivery of ISA247 in  patients suffering from mild to moderate
psoriasis.
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug,  ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of  its products, the Company's expectations regarding the
issuance of  additional patents and the Company's ability to protect
its intellectual  property, involve known and unknown risks and
uncertainties, which could  cause the Company's actual results to
differ materially from those in the  forward-looking statements. Such
risks and uncertainties include, among  others, the availability of
funds and resources to pursue research and  development projects, the
ability to economically manufacture its products,  the potential of
its products, the success and timely completion of  clinical studies
and trials, the Company's ability to successfully  commercialize its
products, the ability of the Company to defend its  patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of  others. Investors should consult the Company's quarterly
and annual filings  with the Canadian commissions for additional
information on risks and  uncertainties relating to the
forward-looking statements. Investors are  cautioned against placing
undue reliance on forward-looking statements.

Contact:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 246, Fax:
+1-(780)-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-(780)-487-1600 Ext. 243, Fax: +1-(780)-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com

Plus de actualités: Isotechnika Inc.
Plus de actualités: Isotechnika Inc.
  • 21.08.2006 – 15:04

    Isotechnika Inc. Announces Promising Results From Phase I TAFA93 Trials

    Edmonton, Alberta (ots/PRNewswire) - - Isotechnika Inc. announced today promising results from its Phase I TAFA93 trials. TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation. mTOR inhibitors are typically used in combination with ...

  • 25.05.2006 – 14:09

    Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin ...

  • 25.04.2006 – 15:21

    Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ...